eXoZymes, Inc. (EXOZ) Stock Price & Analysis
eXoZymes, Inc. (EXOZ) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $2.90 (-14.05%), as of the Nov 20, 2026 trading session; market cap $27.4M.
Educational signal · not a buy or sell recommendation · How to read this
eXoZymes, Inc. · EXOZ · NASDAQ
eXoZymes, Inc. is a synthetic biochemical company focused on developing the SimplePath platform. This platform aims to produce a variety of chemicals, including pharmaceuticals, fuels, and food additives.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · eXoZymes (EXOZ)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet, weak growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Rich; Growth Durability: Fading; Momentum: Slipping.
- Altman Z -7.86 · Piotroski F 1
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.90 | |
| Change on the day | -14.05% | |
| Market capitalisation | $27.4M | — |
| Shares traded on the day | 10.8K |
Price & events
Other perspectives
Council score for eXoZymes (EXOZ): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is eXoZymes (EXOZ), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. eXoZymes, Inc. (EXOZ) is listed on NASDAQ. It employs 32 people. The market values it at $27.4M.
What are the financial strengths and risks for eXoZymes (EXOZ)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -7.86 · Piotroski F 1. Trailing ratios: ROA -74.7% · current ratio 3.81.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -7.86 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at eXoZymes (EXOZ)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -1.19 · 0 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for EXOZ.
Checked against the records this page reads, on the dates shown above.
How does eXoZymes compare with its peers?
Short answer
eXoZymes's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| eXoZymes (EXOZ) — this page | $2.90 | $27.4M | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $0.00
- EPS estimate
- $-1.19
Measured against a quoted price of $2.90 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held EXOZ in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported EXOZ in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about eXoZymes (EXOZ)?
Investor Questions: EXOZ Stock
These answers are editorial: 1 of these 9 answers is drawn from the EXOZ research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for EXOZ?
EXOZ carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. eXoZymes, Inc. is a synthetic biochemical company focused on developing the SimplePath platform.
Is EXOZ a good stock to buy?
Stock Expert AI does not rate EXOZ buy, sell or hold. eXoZymes, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the EXOZ stock price today?
The last price recorded for eXoZymes, Inc. (EXOZ), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What revenue streams does eXoZymes, Inc. have in healthcare?
Currently, eXoZymes, Inc. does not have established revenue streams in the healthcare sector. The company's primary focus is on developing the SimplePath platform and securing partnerships with pharmaceutical companies.
What are the key factors to evaluate for EXOZ?
eXoZymes, Inc. (EXOZ) holds a MoonshotScore in the low range. Not financial advice.
How frequently does EXOZ data refresh on this page?
EXOZ's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven EXOZ's recent stock price performance?
eXoZymes, Inc. (EXOZ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative SimplePath platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EXOZ overvalued or undervalued right now?
eXoZymes, Inc. (EXOZ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of EXOZ?
Fractional-share availability for eXoZymes, Inc. (EXOZ) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 5 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com